CALIFORNIA, US. June 4, 2026 – My Surrogacy Journey and Sapyen have announced a new strategic partnership aimed at improving access to fertility diagnostics and reproductive support services for intended parents. The collaboration brings together one of the world’s most recognized surrogacy organizations and a leading provider of male fertility testing technology, with an initial focus on the U.S. market.
As part of the agreement, Sapyen will provide fertility testing services for My Surrogacy Journey’s intended parents globally. These services include semen analysis, DNA fragmentation testing, and infectious disease screening designed to support reproductive planning and treatment pathways.
The partnership reflects a shared commitment to improving the infrastructure that supports modern fertility and surrogacy care.
Male fertility diagnostics have traditionally been constrained by clinic-based testing models, geographic limitations, and fragmented service delivery. Those challenges can become even more pronounced in surrogacy arrangements, where intended parents often coordinate multiple providers, legal processes, and healthcare systems across international borders.
Both organizations believe patients increasingly require integrated solutions that simplify access to care and create greater continuity throughout their reproductive journey.
My Surrogacy Journey has built a strong international reputation for delivering ethically led surrogacy support through a carefully developed global network. The organization is known for helping intended parents navigate complex pathways with greater clarity, transparency, and consistency.
Sapyen has established itself as a leader in fertility diagnostics infrastructure, supporting clinics, laboratories, and healthcare providers worldwide through advanced at-home testing and preservation solutions.
Its SPX72 stabilization technology allows semen samples to remain viable for analysis for up to 72 hours, creating new opportunities for laboratory-quality testing beyond traditional clinic settings.
“The historical fertility model was built around geography,” said Ash Ramachandran, Founder and CEO of Sapyen. “Patients travelled to infrastructure. The next generation of reproductive medicine will invert that entirely.”
The partnership will launch initially across the United States, with both organizations expecting to identify additional opportunities for collaboration in fertility preservation and reproductive health.
“Surrogacy is one of the most operationally complex categories in reproductive medicine,” Ramachandran continued. “It requires coordination across clinicians, laboratories, legal teams, donors, intended parents, and international jurisdictions simultaneously. Infrastructure quality materially impacts patient outcomes in that environment.
“My Surrogacy Journey has built one of the most sophisticated and trusted platforms globally for navigating that complexity. They are not simply facilitating introductions. They are helping define the operational and ethical standard for modern surrogacy internationally.”
Ramachandran noted that fertility diagnostics and preservation are becoming increasingly central to reproductive healthcare rather than supplementary services.
“For decades, fertility testing and preservation were positioned as reactive services. By the time many patients entered the system, optionality had already narrowed. We believe that changes now. Earlier diagnostics, better biological data, and accessible preservation infrastructure will increasingly become standard entry points into reproductive medicine globally.”
Michael Johnson-Ellis, Co-founder and Co-CEO of My Surrogacy Journey, said the partnership aligns with the organization’s commitment to building a comprehensive support ecosystem for intended parents around the world.
“Our responsibility to intended parents extends far beyond guidance. We are building an ecosystem around them capable of supporting extraordinarily complex journeys with consistency, credibility, and care.
“Sapyen immediately distinguished itself with both its scientific credibility and operational capability to execute fertility diagnostics and preservation at international scale.
“Their infrastructure, laboratory integration, and long-term vision for modern fertility care make them an exceptionally strong partner for My Surrogacy Journey and for the families we support across the world.”
Wes Johnson-Ellis, Co-founder and Co-CEO of My Surrogacy Journey, added that increasingly international fertility journeys require solutions that can function seamlessly across borders.
“Intended parents today are navigating fertility across multiple countries and healthcare systems simultaneously. That requires partners capable of operating with precision internationally. This partnership materially strengthens the level of fertility support available to intended parents navigating increasingly global reproductive pathways.”
The agreement further expands Sapyen’s international presence in fertility diagnostics and reproductive preservation, building on its continued growth across IVF clinic networks, laboratory organizations, benefits providers, and reproductive healthcare partners worldwide.
